【レポートの概要（一部）】
1. Report Overview
1.1 Breast Cancer Drugs Overview
1.2 Why you Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Breast Cancer and its Treatment
2.1 What is Breast Cancer?
2.2 The Second Most Common Cancer in the World
2.3 Normal Structure of the Human Breast
2.4 Classifying the Different Types of Breast Cancer
2.4.1 Pathology
2.4.2 Molecular Subtype
2.4.3 Stages
2.4.4 Grades
2.5 Treatment Protocols
2.5.1 Treatment Options for Localised Disease
2.5.1.1 The Different Types of Therapy for Localised Breast Cancer
2.5.1.2 Stage 0 – Lobular Carcinoma in Situ (LCIS) and Ductal Carcinoma in Situ (DCIS)
2.5.1.3 Adjuvant Chemotherapy and Adjuvant Hormonal Therapy Treatment Options for Stage 1-3 Localised Disease
2.5.2 Treatment Options for Recurrent or Metastatic Disease
3. Leading Breast Cancer Drugs
3.1 Herceptin (trastuzumab) by Roche: The Leading Breast Cancer Drug
3.1.1 Approved Indications: Breast Cancer is the Main Indication
3.1.2 Roche Builds Franchise of Anti-HER2 mAbs Around Herceptin
3.1.3 Total Herceptin Revenues 2010-2015
3.1.4 The Threat of Biosimilars
3.1.4.1 Hertraz and CanMab (Mylan and Biocon): The First to Win Approval
3.1.4.2 Herzuma (Celltrion)
3.1.4.3 Total Biosimilar Trastuzumab Revenue Forecast, for all Indications, 2016-2026
3.1.5 Herceptin for Breast Cancer Revenue Forecast 2016-2026
3.2 Perjeta (pertuzumab) by Roche
3.2.1 Is a Recent Addition to the Market, Approved for Different Stages of Breast Cancer
3.2.2 Positive Results from Different Clinical Trials
3.2.3 Total Perjeta Revenues 2012-2015
3.2.4 Perjeta for Breast Cancer Revenue Forecast 2016-2026
3.3 Afinitor (everolimus) by Novartis
3.3.1 Multiple Approved Indications but Breast Cancer Leads
3.3.2 No Extension to HER2 Positive Breast Cancer, as Afinitor Fails to Meet Primary Objective in Phase 3 Trial
3.3.3 NICE Rejects Afinitor on Cost Basis, although Drug Remains on the Cancer Drugs Fund, Despite Rumours it Would be Removed
3.3.4 Total Afinitor Revenues 2010-2015
3.3.5 Afinitor for Breast Cancer Revenue Forecast 2016-2026
3.4 Faslodex (fulvestrant) by AstraZeneca
3.4.1 Approved for Breast Cancer all the Way Back in 2002, Higher Dose Approved in 2010
3.4.2 Patent Dispute with Mylan
3.4.3 Total Faslodex Revenues 2010-2015
3.4.4 Faslodex for Breast Cancer Revenue Forecast 2016-2026
3.5 Ibrance (palbociclib) by Pfizer
3.5.1 Accelerated Approval on the Back of Promising Data
3.5.2 Has Already Been Used to Treat Over 15,000 Patients, MAA Filed in Europe
3.5.3 Total Ibrance Revenues Q1-Q4 2015
3.5.4 Ibrance for Breast Cancer Revenue Forecast 2016-2026
3.6 Avastin (bevacizumab) by Roche
3.6.1 Multiple Approved Indications, Still Approved for Breast Cancer in Major Markets, Except for the US
3.6.1.1 Why was the FDA-Breast Cancer Label Withdrawn?
3.6.2 Total Avastin Revenues 2010-2015
3.6.3 Avastin for Breast Cancer Revenue Forecast 2016-2026
3.6.4 No Biosimilars Approved yet, but Multiple Candidates in Clinical Trials
3.6.5 Total Biosimilar Bevacizumab Revenue Forecast, for all Indications, 2016-2026
3.7 Kadcyla (ado-trastuzumab emtansine) by Roche
3.7.1 The First Antibody-Drug Conjugate to be Approved for Breast Cancer
3.7.2 Mixed Results from Different Clinical Trials
3.7.3 Total Kadcyla Revenues 2013-2015
3.7.4 Kadcyla for Breast Cancer Revenue Forecast 2016-2026
3.8 Femara (letrozole) by Novartis
3.8.1 Hormone Therapy for Early Breast Cancer
3.8.2 Total Femara Revenues 2010-2025
3.8.3 Femara for Breast Cancer Revenue Forecast 2016-2026
3.9 Abraxane (paclitaxel Protein-Bound) by Celgene
3.9.1 Breast Cancer was the first of its Approved Indications
3.9.2 Total Abraxane Revenues 2010-2015
3.9.3 Abraxane for Breast Cancer Revenue Forecast 2016-2026
4. Breast Cancer Drugs R&D Pipeline 2016-2026
4.1 Roche: Not Content with Dominating Current Market, Already Grooming Future Leaders
4.1.1 Taselisib (GDC-0032 / RG7604)
4.1.1.1 Positive Results from Phase 1 Trial
4.1.2 Atezolizumab (MPDL3280A / RG7446)
4.1.2.1 Early Results in Triple-Negative Breast Cancer
4.1.3 Investigating Kadcyla and Perjeta in Wider Breast Cancer Indications
4.2 Novartis
4.2.1 Buparlisib (BKM120)
4.2.1.1 Early-Results for Buparlisib in Combination with Olaparib
4.2.2 Alpelisib (BYL719)
4.2.3 Ribociclib (LEE011)
4.2.3.1 Phase 1b Results in Combination with Femara
4.3 AstraZeneca
4.3.1 AZD5363
4.3.1.1 Well Tolerated and Yielding Partial Response in Early Results from 2013
4.3.2 MEDI-573 (In Partnership with MedImmune)
4.4 Abemaciclib (LY2835219) by Eli Lilly
4.4.1 Coveted Breakthrough Therapy Designation from the FDA
4.5 Veliparib (ABT-888) by AbbVie
4.6 Ganetespib by Synta Pharmaceuticals
4.7 Entinostat by Syndax Pharmaceuticals
4.7.1 Syndax Collaborating with Merck and Roche, Breakthrough Therapy Designation
4.8 Lucitanib by Clovis Oncology
4.9 Glembatumumab vedotin (CDX-011) by Celldex Therapeutics
4.9.1 Results from EMERGE Study
4.10 MM-302 by Merrimack
4.10.1 Phase 1 Results Released April 2015
4.11 Neratinib (PB272) by Puma Biotechnology
4.12 ENMD-2076 by CASI Pharmaceuticals
4.13 Margetuximab by MacroGenics
5. Global Breast Cancer Drugs Market 2016-2026
5.1 The Global Breast Cancer Drugs Market Forecast 2016-2026
5.2 What Factors will Drive Growth in the Global Breast Cancer Drugs Market?
5.3 Increasing Rate of Breast Cancer
5.3.1 What Factors are Contributing to this Increase?
5.4 Dynamic and Lucrative Sector with Strong R&D Pipeline
5.5 The Use of Combination Therapies Brings Various Benefits to Both Patients and Companies
5.6 What Factors will Restrain Growth in the Breast Cancer Drugs Market?
5.7 Patent Expiries for Key Drugs Will Open up Market to Generic and Biosimilar Competition
5.8 Declining Healthcare Budgets Lead to Cost Pressures
5.9 New Therapies that Only Offer Modest Benefits over Existing Treatments, and Intense Competition
5.10 SWOT Analysis of the Global Breast Cancer Drugs Market
6. Leading Therapeutic Segments and National Markets within the Global Breast Cancer Drugs Market
6.1 The Main Therapeutic Segments within the Breast Cancer Drugs Market, Forecast 2016-2026
6.1.1 Therapeutic Composition of the Market in 2015, 2020 and 2026
6.1.2 Monoclonal Antibodies (mAbs) Segment Forecast 2016-2026
6.1.3 Chemotherapy and Hormone Therapy Segment
6.1.4 Kinase Inhibitor Segment Forecast 2016-2026
6.1.5 ‘Other’ Segment Forecast 2016-2026
6.2 Leading National Markets for Breast Cancer Drugs
6.2.1 Leading Regional Markets for Breast Cancer, Forecast 2016-2026
6.2.2 Regional Composition of the Market in 2015, 2020 and 2026
6.2.3 US Breast Cancer Drugs Market 2016-2026
6.2.3.1 The Dominant National Market, and will Remain so Throughout the Forecast Period, Although is Undergoing Some Changes
6.2.3.2 US Breast Cancer Drugs Market Forecast 2016-2026
6.2.4 EU5 Breast Cancer Drugs Market 2016-2026
6.2.4.1 German Breast Cancer Drugs Market: The Leading EU Market, Undergoing Reforms
6.2.4.2 German Breast Cancer Drugs Market Forecast 2016-2026
6.2.4.3 French Breast Cancer Drugs Market: Some Reduction in Healthcare Spending, but National Healthcare System Remains Strong
6.2.4.4 French Breast Cancer Drugs Market Forecast 2016-2026
6.2.4.5 Italian Breast Cancer Drugs Market: Facing Challenges
6.2.4.6 Italian Breast Cancer Drugs Market Forecast 2016-2026
6.2.4.7 UK Breast Cancer Drugs Market: Pricing is a Contentious Issue
6.2.4.8 UK Breast Cancer Drugs Market Forecast 2016-2026
6.2.4.9 Spanish Breast Cancer Drugs Market
6.2.4.10 Spanish Breast Cancer Drugs Market Forecast 2016-2026
6.2.5 Japanese Breast Cancer Drugs Market
6.2.5.1 Rapidly Ageing Population will Boost the Market, but will a Successful Generic Market be Established?
6.2.5.2 Japanese Breast Cancer Drugs Market Forecast 2016-2026
6.2.6 BRIC Breast Cancer Drugs Market
6.2.6.1 Chinese Breast Cancer Drugs Market: Nation to Become one of the Major Global Players due to Rapid Growth
6.2.6.2 Chinese Breast Cancer Drugs Market Forecast 2016-2026
6.2.6.3 Brazilian Breast Cancer Drugs Market: Healthcare in the Country is Taking Great Strides Forward
6.2.6.4 Brazilian Breast Cancer Drugs Market Forecast 2016-2026
6.2.6.5 Russian Breast Cancer Drugs Market: Punches Below its Weight
6.2.6.6 Russian Breast Cancer Drugs Market Forecast 2016-2026
6.2.6.7 Indian Breast Cancer Drugs Market: Generics are King
6.2.6.8 Indian Breast Cancer Drugs Market Forecast 2016-2026
7. Research Interviews
7.1 Interview with Dr Ken Ren, CEO of CASI Pharmaceuticals
7.1.1 On ENMD-2076 for Triple Negative Breast Cancer
7.1.2 Status of the Chinese Oncology Market
7.1.3 On the Properties that will Allow CASI to compete Against Giants in the Market, Such as Roche
7.1.4 On Drivers and Restraints for the Market
7.1.5 On the Challenges of Developing a Pipeline Product for the Breast Cancer Market, and Ways of Overcoming Them
7.2 Interview with MacroGenics
7.2.1 On Margetuximab for Metastatic Breast Cancer
7.2.2 On Where Margetuximab would fit into the Competitive HER2 Space
7.2.3 On the Challenges of Developing a Pipeline Product
8. Conclusions from Our Research and Analysis
8.1 How will Revenues Change over the Forecast Period?
8.2 How will the Therapeutic Composition of the Market Change over the Forecast Period?
8.3 How will the Composition of the Global Market Change Over the Forecast Period?
8.4 Concluding Remarks
【レポート販売概要】
■ タイトル：乳がん治療薬の世界市場：モノクローナル抗体、ホルモン、化学療法、キナーゼ阻害剤、その他■ 英文：Breast Cancer Drugs Market 2016-2026 : Revenue Forecasts for Monoclonal Antibodies, Hormones, Chemotherapy, Kinase Inhibitors and Other Pharmaceuticals
■ 発行日：2016年3月
■ 調査会社：visiongain
■ 商品コード：VGAIN6041534
■ 調査対象地域：グローバル
- ミクロスフィアの世界市場：中空ミクロスフィア、固体マイクロスフィアRising demand for efficiency and better materials with superior structural properties will drive the global microspheres market to $5.9 billion by 2019. U.S. leads the world in terms of usage of advanced materials to increase the efficiency and reliability of operations which makes it the biggest market for microspheres. The market here is expected to experience highest revenue growth during the n …
- 世界のデータセンター用無停電電源装置 (UPS)市場（2014-2018）About Data Center UPS A data center UPS is the intermediary interface between power mains and data center equipment. Data center UPS systems provide continuous high-quality electrical power which facilitates efficient functioning of an enterprise network. UPS systems are triggered automatically when the power supply is interrupted between the mains and the equipment. Due to the presence of UPS sys …
- バイオマスプラスチックのグローバル市場動向2011-2016（Bioplastics – A Global Market Watch, 2011 – 2016）Global Market Watch: Global Bioplastics market is expected to reach US$7.7 billion by 2016 at a Compounded Annual Growth Rate (CAGR) of 24.3%, globally. Region-wise analysis shows that Asia-Pacific is forecasted to record the highest growth rate of 25.7% during the analysis period 2011-2016. The Americas follows Asia-Pacific with a CAGR of 25.2%. Europe forecasts to drive with a growth rate of 23. …
- 非アルコール性脂肪性肝疾患(NAFLD)：世界の治験レビュー（2015年上半期版）Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015" provides data on the Non Alcoholic Fatty Liver Disease (NAFLD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non Alcoholic F …
- Crocotta Energy Inc.：石油・ガスの開発・生産動向及びコスト分析- Q2, 2013Crocotta Energy Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary Crocotta Energy Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source f …
- 医療機器業界のM&A及び投資動向（年別）：2012Medical Equipment Annual Deals Analysis: M&A and Investments Trends - 2012 Summary GlobalData's “Medical Equipment Annual Deals Analysis: M&A and Investments Trends - 2012” report is an essential source of data and trend analysis on mergers and acquisitions (M&A) and financing in the medical equipment market. The report provides detailed information on M&A, equity/debt offerings, private equity (P …
- 世界の非殺傷兵器市場This report presents a complete analysis of the global non-lethal weapons market across the forecast period. It analyzes the factors driving the market, the challenges faced by the industry, and the factors restraining the growth of the market. It also discusses the key industry trends, market trends, and technology trends that are about to influence the global market. The report provides a comple …
- 世界のエレベータおよびエスカレータ新技術分析2015-2019About elevators and escalators Elevators and escalators are positioned in buildings for the efficient movement of people and goods within these buildings’ premises. Elevators and escalators are installed in commercial buildings, residential buildings, mixed-used buildings, IT parks, hotels, restaurants, and retail outlets. They are also installed in public places to improve vehicle parking managem …
- 石油・ガス上流装置の世界市場2018-2022About Oil and Gas Upstream Equipment Oil and gas upstream equipment is used in various upstream operations, including exploration, drilling, well interventions, well completion, production, and abandonment. The market also includes the tools used in the above-mentioned operations. Technavio’s analysts forecast the global oil and gas upstream equipment market will grow more than USD 211 billion by …
- ステンレス鋼の世界市場2016-2020About Stainless SteelStainless steel is an iron-based alloy containing at least 10.5% chromium by mass. In order to enhance its properties, other alloys like nickel, titanium, columbium, and molybdenum can also be added during melting. Stainless steel is resistive to corrosion, rust, and stain with water unlike ordinary steel, due to which it is used in a number of industries like household applia …
- 消費者向けIoTの世界市場予測（～2023年）“Consumer preference for increased convenience and better lifestyle drives overall consumer IoT market”The consumer IoT market is estimated to be USD 46.8 billion by 2018 and is projected to reach USD 104.4 billion by 2023, at a CAGR of 17.39%. The growth of the consumer IoT market can be attributed to the growing number of internet users and adoption of smart devices, increasing awareness about f …
- レトルト包装の世界市場2016-2020About the Retort Packaging Market Packaging of food products protects them from spoilage and also improves the overall aesthetic appeal of the products. Retort packaging is a heat-resistant pack used for food and beverages packaging. Healthcare packaging, which is laminated inside with multiple layers of flexible plastic and metal foils, can withstand high temperatures and pressures. The multiple …
- 脂肪代替品の世界市場予測（～2022年）：炭水化物系、タンパク質系、脂質系The global fat replacers market witnessed steady growth over the last few years. The market size is estimated to be 1.48 Billion in 2017, and is projected to reach USD 2.01 Billion by 2022, at a CAGR of 6.2% from 2017. Increasing prevalence of obesity and the growing awareness about health and wellness are the major drivers contributing to the growth of this market. The fat replacers market, by ty …
- 北米の防火システム市場The North America Fire protection systems market has been broadly classified into components and services. The components market is estimated to account for the larger share of the North America Fire protection systems market in 2014. However, the services market is expected to grow at a higher CAGR in the next five years, owing to factors such as increased time consumption, lack of resources, and …
- 世界のマザーボード市場予測This report presents worldwide motherboard shipment volume per year for the period 2015 - 2019 and per quarter for the period 1Q 2012 - 2Q 2015. Also included are forecast and recent years' review of worldwide shipment volume and share by region and by CPU connector type, as well as motherboard vs. desktop PC shipment volume ratio on the global basis. This research finds that worldwide commercial …
